Concepedia

Publication | Closed Access

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

DOI

60

Citations

0

References

2020

Year

Ben Tran, Lisa G. Horvath, Tanya B. Dorff, M. Rettig, Martijn P. Lolkema, J-P. Machiels, Sylvie Rottey, Karen A. Autio, Richard Greil, Nabil Adra,
Annals of Oncology

No additional data available for this publication yet. Check back later!